RadNet (RDNT) Competitors $55.65 +0.03 (+0.05%) Closing price 04:00 PM EasternExtended Trading$55.66 +0.02 (+0.03%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RDNT vs. HIMS, GH, OPCH, BTSG, SHC, CON, PRVA, SGRY, WGS, and VCYTShould you be buying RadNet stock or one of its competitors? The main competitors of RadNet include Hims & Hers Health (HIMS), Guardant Health (GH), Option Care Health (OPCH), BrightSpring Health Services (BTSG), Sotera Health (SHC), Concentra Group Holdings Parent (CON), Privia Health Group (PRVA), Surgery Partners (SGRY), GeneDx (WGS), and Veracyte (VCYT). These companies are all part of the "healthcare" industry. RadNet vs. Its Competitors Hims & Hers Health Guardant Health Option Care Health BrightSpring Health Services Sotera Health Concentra Group Holdings Parent Privia Health Group Surgery Partners GeneDx Veracyte RadNet (NASDAQ:RDNT) and Hims & Hers Health (NYSE:HIMS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership. Which has more volatility and risk, RDNT or HIMS? RadNet has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500. Comparatively, Hims & Hers Health has a beta of 2.03, suggesting that its share price is 103% more volatile than the S&P 500. Is RDNT or HIMS more profitable? Hims & Hers Health has a net margin of 9.24% compared to RadNet's net margin of -1.73%. Hims & Hers Health's return on equity of 22.75% beat RadNet's return on equity.Company Net Margins Return on Equity Return on Assets RadNet-1.73% 1.41% 0.48% Hims & Hers Health 9.24%22.75%15.51% Do institutionals and insiders believe in RDNT or HIMS? 77.9% of RadNet shares are held by institutional investors. Comparatively, 63.5% of Hims & Hers Health shares are held by institutional investors. 5.6% of RadNet shares are held by company insiders. Comparatively, 17.7% of Hims & Hers Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has preferable earnings & valuation, RDNT or HIMS? Hims & Hers Health has lower revenue, but higher earnings than RadNet. RadNet is trading at a lower price-to-earnings ratio than Hims & Hers Health, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRadNet$1.83B2.28$2.79M-$0.43-129.42Hims & Hers Health$1.48B7.19$126.04M$0.6968.77 Does the media refer more to RDNT or HIMS? In the previous week, Hims & Hers Health had 87 more articles in the media than RadNet. MarketBeat recorded 92 mentions for Hims & Hers Health and 5 mentions for RadNet. RadNet's average media sentiment score of 1.22 beat Hims & Hers Health's score of 0.18 indicating that RadNet is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RadNet 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Hims & Hers Health 12 Very Positive mention(s) 9 Positive mention(s) 62 Neutral mention(s) 6 Negative mention(s) 2 Very Negative mention(s) Neutral Do analysts prefer RDNT or HIMS? RadNet presently has a consensus price target of $69.60, indicating a potential upside of 25.07%. Hims & Hers Health has a consensus price target of $39.58, indicating a potential downside of 16.58%. Given RadNet's stronger consensus rating and higher probable upside, equities research analysts clearly believe RadNet is more favorable than Hims & Hers Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RadNet 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 3 Strong Buy rating(s) 3.50Hims & Hers Health 3 Sell rating(s) 8 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 1.92 SummaryHims & Hers Health beats RadNet on 10 of the 17 factors compared between the two stocks. Get RadNet News Delivered to You Automatically Sign up to receive the latest news and ratings for RDNT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RDNT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RDNT vs. The Competition Export to ExcelMetricRadNetMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.18B$3.90B$5.49B$8.93BDividend YieldN/A1.28%5.38%4.12%P/E Ratio-129.4235.0026.2019.89Price / Sales2.2899.96415.50166.23Price / Cash16.3425.2836.4957.06Price / Book3.634.388.055.39Net Income$2.79M$189.47M$3.15B$248.50M7 Day Performance-0.80%-2.66%1.92%2.96%1 Month Performance-4.48%-4.22%4.90%6.02%1 Year Performance-6.52%7.95%35.95%20.44% RadNet Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RDNTRadNet4.2325 of 5 stars$55.65+0.1%$69.60+25.1%-5.0%$4.18B$1.83B-129.4211,021Positive NewsAnalyst DowngradeHIMSHims & Hers Health2.1067 of 5 stars$42.09-34.5%$38.00-9.7%+123.5%$9.42B$1.48B61.001,637Trending NewsInsider TradeHigh Trading VolumeGHGuardant Health3.622 of 5 stars$48.57-1.2%$53.76+10.7%+79.4%$6.02B$774.00M-14.332,021OPCHOption Care Health4.1209 of 5 stars$31.05-1.5%$35.50+14.3%+16.9%$5.08B$5.19B25.048,088Positive NewsBTSGBrightSpring Health Services1.6146 of 5 stars$22.77+2.2%$24.90+9.4%+103.2%$4.00B$11.27B81.3235,000SHCSotera Health3.0969 of 5 stars$11.09-2.6%$15.80+42.5%-1.1%$3.15B$1.10B138.643,000CONConcentra Group Holdings Parent3.3206 of 5 stars$20.95+1.0%$28.50+36.0%N/A$2.69B$1.90B15.6311,250PRVAPrivia Health Group4.2618 of 5 stars$21.61-1.1%$27.77+28.5%+31.8%$2.63B$1.74B180.101,140News CoverageSGRYSurgery Partners2.4002 of 5 stars$20.20+4.7%$33.56+66.1%-3.7%$2.59B$3.11B-13.2015,000WGSGeneDx1.8822 of 5 stars$79.71+19.0%$86.75+8.8%+214.7%$2.27B$305.45M-56.531,200Analyst ForecastGap DownHigh Trading VolumeVCYTVeracyte3.4973 of 5 stars$26.71+1.2%$40.90+53.1%+28.1%$2.09B$445.76M65.15790 Related Companies and Tools Related Companies Hims & Hers Health Alternatives Guardant Health Alternatives Option Care Health Alternatives BrightSpring Health Services Alternatives Sotera Health Alternatives Concentra Group Holdings Parent Alternatives Privia Health Group Alternatives Surgery Partners Alternatives GeneDx Alternatives Veracyte Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RDNT) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersSomething very strange is happening...What a "Mar-a-Lago Accord" could mean for the U.S. dollar While protests dominate the news... hardly anyone...Stansberry Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RadNet, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share RadNet With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RDNT Stock Alerts